Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 + Low-dose Cytarabine in Elderly AML
NCT01488344Phase 2Unknown
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2012
- Primary completion
- Nov 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in acute myeloid leukemia (AML), sponsored by Universitätsklinikum Münster. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Overall Response Rate at 6 months. Status: unknown.
02
Drugs
nintedanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01488344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488344.